Metagenomi Therapeutics (MGX) Operating Income (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Operating Income of -$24.6 million for Q1 2026, up 11.62% year-over-year from -$22.0 million in Q1 2025, and down 0.9% quarter-over-quarter from -$24.4 million in Q4 2025.
Metagenomi Therapeutics (MGX) Operating Income (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Operating Income for 4 consecutive years, with -$24.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 11.62% year-over-year to -$24.6 million; the TTM figure through Mar 2026 stood at -$92.8 million (down 5.81% YoY), while the FY2025 annual figure was -$96.0 million, down 8.0% from the prior year.
- Operating Income fell to -$24.6 million in Q1 2026 per MGX's latest filing, from -$24.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$16.9 million in Q2 2024 and bottomed at -$29.0 million in Q1 2024.
- Historically, Operating Income has averaged -$22.2 million across 4 years, with a median of -$22.4 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Income tumbled 61.85% — and 2026, when it advanced 11.62%.
- Metagenomi Therapeutics' Operating Income stood at -$20.2 million in 2023, then dropped by 2.11% to -$20.6 million in 2024, then retreated by 18.15% to -$24.4 million in 2025, then retreated by 0.9% to -$24.6 million in 2026.
- Business Quant data shows MGX's Operating Income at -$24.6 million in Q1 2026, -$24.4 million in Q4 2025, and -$22.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | Metagenomi Therapeutics | 46.66 Mn | 46.66 Mn | - | -28.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.77 Mn |
| Mar 31, 2026 | -24.59 Mn |
| Dec 31, 2025 | -24.37 Mn |
| Sep 30, 2025 | -22.84 Mn |
| Jun 30, 2025 | -20.99 Mn |
| Mar 31, 2025 | -27.82 Mn |
| Dec 31, 2024 | -20.62 Mn |
| Sep 30, 2024 | -22.38 Mn |
| Jun 30, 2024 | -16.86 Mn |
| Mar 31, 2024 | -29.03 Mn |
| Dec 31, 2023 | -20.20 Mn |
| Sep 30, 2023 | -22.40 Mn |
| Jun 30, 2023 | -17.96 Mn |
| Mar 31, 2023 | -17.94 Mn |